

## Special Issue

# The Recent Updates in Glioblastoma Management

### Message from the Guest Editor

Gliomas present the most common primary malignant tumor in the brain, characterized by high intra- and inter-heterogeneity, high recurrence rate and mortality, and easy resistance to conventional treatment. Although studies in the past two decades have revealed the effectiveness of many predictive markers, such as IDH mutation status, chromatin 1p/19q deletion status, and methylation status of MGMT promoters, in clinical diagnosis, treatment, and prognosis of glioma patients, and multimodal therapeutic strategies including surgery combined with radio- and chemotherapy, the clinical efficacy of gliomas is still not ideal, and the prognosis of patients has not been significantly improved. More and more evidence has supported the idea that the individual precise therapeutic strategies under the guidance of special markers offer a promising avenue of glioma diagnosis and treatment. The topic of this Special Issue is “Recent Updates in Glioblastoma Management”, aiming to collect reviews and original articles related to glioma basic research and clinical translations.

### Guest Editor

Prof. Dr. Chunsheng Kang

Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China

### Deadline for manuscript submissions

closed (17 April 2023)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/120168](https://mdpi.com/si/120168)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).